Models of survival in HIV infection and their use in the quantification of treatment benefits

American Journal of Epidemiology

Volumn 148, Issue 5, 1998, Pages 487-496

  Veugelers, Paul J ^a,b,c   Cornelisse, Peter G A ^a   Craib, Kevin J P ^a   Marion, Stephen A ^b   Hogg, Robert S ^a,b   Strathdee, Steffanie A ^a,b   Montaner, Julio S G ^a,b   O'Shaughnessy, Michael V ^a,b   Schechter, Martin T ^a,b  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Acquired immunodeficiency syndrome; Age factors; Back calculation; HIV; Mortality; Projection; Zidovudine

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; DISEASE COURSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; SEROCONVERSION; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 0032168866     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.aje.a009674     Document Type: Article

References (40)

1. Veugelers PJ, Schechter MT. The incubation period of HIV infection. Curr Opin Infect Dis 1997;10:7-11.
2. Muñoz A, Sabin CA, Phillips AN. The incubation period of AIDS. AIDS 1997;11(suppl A):S69-S76.
3. Centers for Disease Control. Revision of the case definition of acquired immuno deficiency syndrome for national reporting -United States. MMWR 1985;34:373-5.
4. Centers for Disease Control. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR 1987;36:1S-15S.
5. Centers for Disease Control. Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992;41/RR-17:1-19.
6. Sheppard HW, Winkelstein W, Osmond D, et al. Effect of new AIDS case definition on the numbers of cases among homosexual and bisexual men in San Francisco. JAMA 1991;266: 2221.
7. Van Griensven GJP, Boucher EC, Roos M, et al. Expansion of the AIDS case definition. Lancet 1991;338:1011-12.
8. + lymphocyte endpoints and AIDS in cohorts of homosexual men. AIDS 1993; 7:1325-9.
9. Biggar RJ. AIDS incubation in 1891 HIV seroconverters from different exposure groups. International Registry of Seroconverters. AIDS 1990;4:1059-66.
10. Jason J, Lui K, Ragni MV, et al. Risk of developing AIDS in HIV-intected cohorts of hemophilic and homosexual men. JAMA 1989;261:725-7.
11. Galia N, Vlahov D, Margolick JB, et al. Changes in markers of disease progression in HIV-1 infected seroconverters: a comparison between cohorts of injecting drug users andhomosexual men. J Acquir Defic Syndr Hum Retrovirol 1995;8:66-74.
12. Chaisson RE, Keruly JC, Moore RD. Race, sex, drug use, and progression of human immunodeficiency virus disease. N Engl J Med 1995;333:751-6.
13. Operskalski EA, Stram DO, Lee H, et al. Human immunodeficiency virus type 1 infection: relationship of risk group and age to rate of progression to AIDS. J Infect Dis 1995;172: 648-55.
14. Pezzotti P, Phillips AN, Dorrucci M, et al. Category of exposure to HIV and age in the progression to AIDS: longitudinal study of people with known dates of seroconversion. Br Med J 1996;313:583-6.
15. Hessol NA, Palacio H. Gender, ethnicity and transmission category variation in HIV disease progression. AIDS 1996; 10(suppl A):S69-S74.
16. Spijkerman IJB, Langendam MW, Veugelers PJ, et al. Differences in progression to AIDS between injection drug users and homosexual men with documented dates of seroconversion. Epidemiology 1996;7:571-7.
17. Prins M, Veugelers PJ. Comparison of progression and nonprogression among injection drug users and homosexual men with documented dates of HIV-1 seroconversion. AIDS 1997; 11:621-31.
18. Schechter MT, Craib KJP, Le TN, et al. Influence of zidovudine on progression to AIDS in cohort studies. Lancet 1989; 1:1026-7.
19. Munoz A, Xu J. Models for the incubation period of AIDS and variations according to age and period. Stat Med 1996;15: 2459-73.
20. Hendriks JCM, Satten GA, Longini IM Jr, et al. Use of immunological markers and continuous-time Markov models to estimate progression of HIV infection in homosexual men. AIDS 1996;10:649-56.
21. Hessol NA, Koblin BA, van Griensven GJP, et al. Progression of human immunodeficiency virus type 1 (HIV-1) infection among homosexual men in hepatitis B vaccine trial cohorts in Amsterdam, New York City, and San Francisco, 1978-1991. Am J Epidemiol 1994;139:1077-87.
22. Schechter MT, Craib KJP, Le TN, et al. Progression to AIDS and predictors of AIDS in seroprevalent and seroincident cohorts of homosexual men. AIDS 1989;3:347-53.
23. Schechter MT, Marion SA, Elmslie KD, et al. How many persons in Canada have been infected with HIV? An exploration using back calculation methods. Clin Invest Med 1992; 15:331-45.
24. Hendriks JCM, Medley GF, van Griensven GJP, et al. The treatment-free incubation period of AIDS in a cohort of homosexual men. AIDS 1993;7:231-9.
25. van Benthem BH, Veugelers PJ, Schechter MT, et al. Modelling the AIDS incubation time: evaluation of three right censoring strategies. AIDS 1997;11:834-5.
26. Saah AJ. Editorial: highlights in 1996. Curr Opin Infect Dis 1997;10:5-6.
27. Muñoz A, Hoover DR. AIDS clinical trials: use of cohort studies for evaluating AIDS therapies. New York: Wiley-Liss, 1995.
28. Statistics Canada. Postcensual annual estimates of population by marital status, age, sex and components of growth for Canada, provinces and territories, 1981-1994. Ottawa: Demographic Division, Statistics Canada, 1981-1994.
29. World Health Organization. International classification of diseases, 9th revision. Geneva: World Health Organization, 1977.
30. Remis RS, Palmer RWH. Modelling AIDS mortality from survival analysis to evaluate completeness of reporting. (Abstract). VII International Conference of AIDS, Florence, June 1991;WC 97.
31. Le TN, Uh SH, Hogg RS, et al. Near-complete reporting of HIV/AIDS deaths in a province-wide treatment program. (Abstract). XI International Conference on AIDS, Vancouver, BC, July 7-12, 1996;Mo.C.1545.
32. Brookmeyer R, Gail MH. Minimum size of the acquired immune deficiency syndrome (AIDS) epidemic in the United States. Lancet 1986;333:1320-2.
33. Brookmeyer R. Reconstruction and future trends of the AIDS epidemic in the United States. Science 1991;253:37-42.
34. Bacchetti P, Segal MR, Hessol NA, et al. Different AIDS incubation periods and their impacts on reconstructing human immunodeficiency virus epidemics and projecting AIDS incidence. Proc Natl Acad Sci USA 1993;90:2194-6.
35. Marion SA, Schechter MT. Use of back calculation for estimation of the probability of progression from HIV infection to AIDS. Stat Med 1993;12:617-31.
36. Hogg RS, O'Shaughnessy MV, Gataric N, et al. Decline in deaths from AIDS due to new antiretrovirais. (Letter). Lancet 1997;349:1294.
37. Buchbinder SP, Katz MH, Hessol NA, et al. Long-term HIV-1 infection without immunologic progression. AIDS 1994;8: 1123-8.
38. + cell counts. J Infect Dis 1994;169:1236-43.
39. Schager LK, Young JM, Fowler MG, et al. Long-term survivors of HIV-1 infection: definitions and research challenges. AIDS 1994;8(Suppl 1):S95-S108.
40. Strathdee SA, Craib KJP, Hogg RS, et al. Longterm nonprogression in HIV infection. (Letter). Lancet 1995;346:1372.